Therapeutic Applications of Interleukin-12 (IL-12)
Giorgio Trinchieri and Bice Perussia
IL-12, a cytokine that may be useful for treatment of certain diseases or for enhancing the immune response, was developed by researchers at The Wistar Institute. IL-12 is a heterodimeric protein, composed of a heavy chain (p40 subunit) and a light chain (p35 subunit) and was originally described as Natural Killer Stimulatory Factor (NKSF). Wistar is an owner of a series of U.S. and international patents on the IL-12 genes, IL-12 proteins (p35 and p40 subunits) and the uses of these compositions for treatment of a variety of conditions such as cancer and infection. Additionally, Wistar is an owner of a series of issued patents for the use of IL-12 as an adjuvant. These patents are available for license to companies developing products that incorporate IL-12.
IL-12, in combination with other agents, may have applications for cancer therapy, immunotherapy and vaccine adjuvant use.
A non-exclusive license to the technology is available for organizations that are developing products containing one or more IL-12 subunits or a gene expressing an IL-12 subunit.